rs10509373 (LRMDA): tamoxifen survival link

Key takeaways

• rs10509373 is linked to longer recurrence-free survival when patients have the C allele.
• The effect size is 4.51 with p=6.29e-9.
• It is a common variant at 10q22 in gene LRMDA.
• Associations are seen in Japanese breast cancer patients on tamoxifen.
• No direct treatment recommendation.

What the research says rs10509373 in LRMDA on chromosome 10q22 is associated with recurrence-free survival in Japanese breast cancer patients receiving tamoxifen. [PMID 22180457] The variant shows a hazard ratio of 4.51 per C allele with p=6.29e-9. [PMID 22180457]

Reported associations recurrence-free survival: The C allele is linked to shorter recurrence-free survival when patients are treated with tamoxifen, hazard ratio 4.51 (p=6.29e-9). [PMID 22180457]

Evidence quality The GWAS included 462 Japanese breast cancer patients receiving adjuvant tamoxifen and replicated the association in two independent sets of 105 and 117 cases. The combined analysis gave a hazard ratio per C allele of 4.51 (95% CI 2.72-7.51, p=6.29e-9). No conflicting findings were reported.

Drug response and pharmacogenomics Patients with the CC genotype may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. [PharmGKB annotation_1] Patients with the CT genotype may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. [PharmGKB annotation_2] Patients with the TT genotype may have longer recurrence-free survival times when treated with tamoxifen as compared to patients with the CC or CT genotype. [PharmGKB annotation_3]

Last lifestyle considerations on file for this variant.